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preceding earliest behavioural deficits and neuronal loss. 
UPS impairment was accompanied by accumulation of pol-
yubiquitinated substrates and found to affect both neuronal 
and astrocytic cell populations. In prion-infected CAD5 
cells, we demonstrate that activation of the UPS by the 
small molecule inhibitor IU1 is sufficient to induce clear-
ance of polyubiquitinated substrates and reduce misfolded 
PrPSc load. Taken together, these results identify the UPS as 
a possible early mediator of prion pathogenesis and prom-
ising target for development of future therapeutics.
Keywords Prion · PrP · UPS · Proteasome · 
Neurodegeneration
Introduction
Impairment of the ubiquitin–proteasome system (UPS) has 
been implicated in a variety of neurodegenerative disor-
ders including Alzheimer’s, Parkinson’s, Huntington’s and 
prion diseases. The UPS is a highly conserved and tightly 
regulated pathway in which covalent conjugation of a poly-
ubiquitin chain to redundant or misfolded proteins leads to 
rapid degradation by the 26S proteasome [9]. Despite het-
erogeneity in clinical presentation, different neurodegen-
erative disorders are characterised by the accumulation of 
ubiquitinated conjugates in post-mortem brain tissue [31]. 
In the case of certain human prion diseases, ubiquitin is 
deposited as coarse granules at the periphery of prion amy-
loid plaques, which are composed of disease-associated 
PrPSc, a misfolded and aggregation-prone conformer of the 
normal cellular protein, PrPC [20, 37]. These observations 
gave rise to the hypothesis that UPS impairment may con-
tribute to neurotoxicity in prion diseases through a progres-
sive loss of cellular proteostasis.
Abstract Prion diseases are a group of fatal neurode-
generative disorders characterised by the accumulation of 
misfolded prion protein (PrPSc) in the brain. The critical 
relationship between aberrant protein misfolding and neu-
rotoxicity currently remains unclear. The accumulation of 
aggregation-prone proteins has been linked to impairment 
of the ubiquitin–proteasome system (UPS) in a variety of 
neurodegenerative disorders, including Alzheimer’s, Par-
kinson’s and Huntington’s diseases. As the principal route 
for protein degradation in mammalian cells, this could 
have profound detrimental effects on neuronal function and 
survival. Here, we determine the temporal onset of UPS 
dysfunction in prion-infected UbG76V-GFP reporter mice, 
which express a ubiquitin fusion proteasome substrate to 
measure in vivo UPS activity. We show that the onset of 
UPS dysfunction correlates closely with PrPSc deposition, 
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A number of studies in cellular and animal models pro-
vide evidence to suggest that UPS dysfunction may be 
important in prion disease pathogenesis. Mice infected 
with the ME7 prion strain show impairment of proteasome 
chymotrypsin-like and caspase-like activities and increased 
levels of ubiquitinated conjugates [22]. We replicated these 
findings in the brains of wild-type mice infected with the 
RML prion strain, confirming that proteasome impairment 
is a general feature of prion disease pathogenesis, rather 
than specific to a single prion strain [24]. Co-immunopre-
cipitation experiments demonstrated a direct interaction 
between PrPSc and components of the 26S proteasome 
in brains of prion-infected mice [7]. In follow-up experi-
ments, we identified a novel mechanism of proteasome 
impairment in which aggregated β-sheet-rich PrP inhibits 
the proteasome by stabilising the closed conformation of 
the substrate entry channel [7]. Consistent with a loss of 
proteasome activity, levels of the short-lived endogenous 
proteasomal substrates p27, p53 and IĸBα are elevated in 
the brains of mice infected with the RML prion strain [7]. 
Aberrant accumulation of such critical short-lived proteins 
could be a key source of neurotoxicity in prion disease 
pathogenesis.
Various transgenic UPS reporter mouse lines have been 
developed to measure the functional status of the UPS 
in vivo. UbG76V-GFP transgenic mice express a reporter 
protein with a ubiquitin fusion degradation (UFD) signal, 
consisting of an N-terminally linked ubiquitin moiety for 
accepting polyubiquitin chains linked through the canoni-
cal Lys48 and less common Lys29 linkages [28]. Previ-
ously, we infected these mice with the 22L prion strain 
and observed evidence of UPS impairment in brain regions 
with the greatest PrPSc deposition at end-stage disease [24]. 
UPS dysfunction is associated with multifactorial toxicity 
including aberrant mitochondrial quality control [3, 39], 
loss of synaptic plasticity [1, 19], amino acid shortage [38] 
and ER stress [18, 26, 35]. We therefore hypothesised that 
UPS impairment may occur early in the course of prion dis-
ease pathogenesis and thus contribute to a progressive loss 
of neuronal function. The aim of the present study was to 
determine the temporal onset of UPS dysfunction in RML 
prion-infected mice by quantifying UbG76V-GFP reporter 




UbG76V-GFP/1 mice [28] are congenic on a C57BL/6N 
background and were maintained as heterozygotes by 
back-crossing to the same wild-type strain. Animals were 
housed in individually ventilated cages with dust-free 
autoclaved wood bedding and had free access to food and 
water. The biological services facility was maintained 
at a constant temperature of 19–23 °C with 55 ± 10 % 
humidity in a 12-h light/dark cycle. Following isolation 
of genomic DNA from an ear-punch, animals were geno-
typed by PCR at 4 weeks of age. Primers for UbG76V-GFP/1 
transgene: 5′-CCTACAGCTCCTGGGCAACGT-3′ and 
5′-TCGACCAAGCTTCCCCACCAC-3′.
Prion inoculation of mice
RML prion inoculum (I6200) was prepared and titrated 
as described previously [4]. Female mice were inoculated 
intra-cerebrally with 30 μl of 1 % RML prion-infected 
brain homogenate or 1 % uninfected brain homogenate 
(control) between 8 and 10 weeks of age. Groups of five 
mice were killed by exposure to rising concentration of 
CO2 at designated serial time points (8, 12 and 18 weeks 
post-inoculation) or at onset of end-stage disease (mean 
onset: 23 weeks post-inoculation). Brains were removed 
and divided sagitally with one hemisphere fixed in 10 % 
(v/v) buffered formal-saline (BFS) for 48 h at room tem-
perature and the other hemisphere fixed in 4 % paraform-
aldehyde in Sorensen phosphate buffer overnight at 4 °C. 
A replicate cohort of animals were inoculated and culled in 
parallel to provide unfixed tissue for western blotting and 
proteasome activity assays.
Burrowing behaviour testing
Burrows consisted of 200 mm long, 68 mm diameter black 
plastic tubes, raised at one end by a 30 mm plastic support. 
The lower end of the tube was sealed with a plastic cap. 
Mice were habituated by placing burrows filled with food 
pellets into group housed cages for two consecutive nights. 
For individual testing, burrows filled with 200 g food pel-
lets were placed in single-housed cages 4 h before the dark 
cycle. The percentage of food pellets displaced over 24 h 
was calculated by measuring the weight of pellets left in 
the tube.
Tissue preparation
BFS-fixed hemispheres were dehydrated by passing 
through a series of industrial methylated spirits (70, 90 and 
100 %) and cleared in xylene. Brain tissue was impreg-
nated with molten paraffin wax and embedded in the sagit-
tal orientation. 4-µm tissue sections were prepared using a 
Leica RM2135 microtome, floated in water at 40 °C and 
mounted on Superfrost™ microscope slides (Thermo Sci-
entific). Mounted sections were left to air dry at 37 °C for 
2 h and 60 °C for 16 h.
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PFA-fixed hemispheres were immersed in 30 % (w/v) 
sucrose for 72 h for cryoprotection and then in Optimal 
Cutting Temperature (OCT, Tissue Tek). 30 µm sagittal 
cryosections were prepared using a Bright OTF5000 cry-
ostat and placed in a solution containing 30 % glycerol, 
30 % ethylene glycol, 30 % ddH2O and 10 % phosphate 
buffer at pH 7.2.
PrPSc immunohistochemistry
Paraffin-embedded tissue sections were pre-treated with 
Tris-Citrate EDTA buffer for antigen retrieval [42]. PrPSc 
deposition was visualised using anti-PrP monoclonal anti-
body ICSM35 (D-Gen Ltd; 1 in 1000) on automated immu-
nohistochemistry staining machines (Ventana Benchmark, 
Roche, Burgess Hill, UK) using proprietary reagents, as 
previously described [42].
Immunofluorescence staining of cryosections
Immunofluorescence staining was performed by pre-
treating free-floating sections with 0.1 % Triton X-100 for 
15 min and 1 M glycine for 30 min at room temperature. 
Sections were then incubated in blocking solution (1 % 
bovine serum albumin and 0.1 % Triton X-100) for 1 h. 
Next, sections were incubated with primary antibodies in 
blocking solution for 16 h at 4 °C (Table S1). Sections were 
then washed in PBS and incubated with secondary antibod-
ies diluted in PBS for 1 h in the dark at room temperature 
(Table S2).
RNA in situ hybridisation
4 micrometre paraffin-embedded sections were used to 
perform RNA in situ hybridisation using the QuantiGene 
viewRNA kit (Affymetrix). ViewRNA probe sets specific 
for eGFP, Actb and Gapdh sequences were designed by 
Affymetrix and RNA in situ hybridisation was performed 
according to manufacturer’s instructions.
Image acquisition and analysis
Confocal images of RNA in situ hybridisation and immu-
nofluorescent staining were acquired with a Zeiss LSM 710 
confocal microscope equipped with 405, 458, 488, 514, 
561 and 633 nm laser lines. For immunofluorescent stain-
ing experiments, three fields of view were imaged across 
the thalamic region using a Plan-Apochromat 20× objec-
tive. Six serial sagittal sections were imaged per animal, 
separated by 300 μm intervals. For RNA in situ hybridisa-
tion experiments, Fast Red (514 nm laser) and Fast Blue 
(633 nm laser) substrates were visualised in six fields of 
view across the thalamic region using a Plan-Apochromat 
40×/1.4 Oil DIC objective. Zeiss Immersol™ 518F was 
used as imaging medium. Two consecutive sagittal sec-
tions were imaged per animal. All images were taken 
with constant gain and pinhole settings at a resolution of 
1024 × 1024 pixels. Bright-field images of DAB-labelled 
and H & E-stained sections were acquired using the Leica 
SCN400F Slide Scanner at 40× magnification.
Confocal images were processed using Volocity® soft-
ware (PerkinElmer, version 6.1.1). To identify cells with 
accumulation of the UbG76V-GFP reporter, anti-GFP stain-
ing intensity was measured in populations of NeuN- and 
GFAP-labelled objects. An intensity value of three stand-
ard deviations greater than the population mean for unin-
fected control mice at 8 weeks post-inoculation was set as 
the threshold for classifying a cell as UbG76V-GFP-positive.
CAD5 cell culture and methods
CAD5 cells were grown in OptiMEM, 10 % foetal bovine 
serum (FBS) and 1x penicillin/streptomycin. CAD5 cells 
were chronically infected with RML prions (ScCAD5) as 
described [14]. CAD5 and ScCAD5 cells were treated with 
the proteasome inhibitor lactacystin (1 μM), the protea-
some activator IU1 (50 μM), or both lactacystin (1 μM) 
and IU1 (50 μM), in 0.5 % DMSO vehicle for 16 h. Vehi-
cle-only control cultures were treated with 0.5 % DMSO 
for 16 h. Cells were collected in PBS and centrifuged at 
10,000×g for 1 min.
Proteasome activity assays
UbG76V‑GFP mouse brain tissue
Animals were culled by exposure to rising concentration of 
CO2. Brains were removed and the thalamus dissected in ice-
cold PBS using a dissection microscope. 10 % (w/v) homoge-
nates were prepared in ice-cold proteasome assay lysis buffer 
(50 mM Tris–HCl, 5 mM MgCl2, 250 mM sucrose, 2 mM 
ATP at pH 7.4) and centrifuged at 13,000×g for 20 min at 
4 °C. Resulting supernatants were placed on ice and total 
protein concentrations measured using the Bio-Rad Protein 
Assay. For determination of proteasome activity, supernatants 
were adjusted to 1 mg/ml total protein by dilution in protea-
some assay lysis buffer supplemented with 1 mM DTT. To 
measure the rate of hydrolysis, 10 μg sample was incubated 
with 100 μM of a fluorogenic peptide substrate in 100 μl 
proteasome assay reaction buffer (50 mM Tris–HCl, 5 mM 
MgCl2, 1 mM DTT, 2 mM ATP at pH 7.4). Chymotrypsin-
like activity was determined using the substrate Suc-LLVY-
aminomethylcoumarin (AMC) (Enzo Life Sciences); 
caspase-like activity was determined using the substrate Ac-
Nle-Pro-Nle-Asp-AMC (Bachem) and trypsin-like activity 
was determined using the substrate Boc-Leu-Arg–Arg-AMC 
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(Enzo Life Sciences). Samples were incubated for 1 h at 
37 °C and the release of AMC measured at 1-min inter-
vals in a TECAN 96-well plate reader (360 nm excitation; 
465 nm emission). All assays were performed in triplicate. 
Background activity caused by non-proteasomal degradation 
was determined by addition of 5 μM epoxomicin (Enzo) for 
30 min at 37 °C. Mean fluorescence values were calculated 
per sample by measuring the mean fluorescence generated in 
the linear reaction phase across triplicate wells. To calculate 
specific proteasome catalytic activities, mean fluorescence 
values of epoxomicin-treated controls were subtracted from 
each sample. Catalytic activity was then expressed as a per-
centage, relative to the mean of the control-inoculated group.
CAD5 cells
CAD5 or ScCAD5 cells were treated with IU1 (50 μM) 
or 0.5 % DMSO vehicle for 16 h, collected in ice-cold 
PBS and centrifuged at 10,000×g for 1 min. Cells were 
re-suspended in proteasome assay lysis buffer and passed 
through a 27G gauge needle ten times. The homogenate 
was then centrifuged at 20,000×g for 20 min. The protea-
some activity of the resulting supernatants was determined 




Animals were culled by exposure to rising concentra-
tion of CO2. Brains were removed and the thalamus dis-
sected in ice-cold PBS using a dissection microscope. 
10 % (w/v) homogenates were prepared in ice-cold tissue 
lysis buffer (100 mM Tris–HCl, 100 mM NaCl, 1 % Triton 
X-100, 10 mM EDTA at pH 7.4) supplemented with cOm-
plete Mini protease and PhosSTOP phosphatase inhibitors 
(Roche) and centrifuged at 13,000×g for 20 min at 4 °C. 
The resulting supernatants were stored on ice and total 
protein concentrations determined using the Bio-Rad Pro-
tein Assay. Samples were adjusted to 1 mg/ml total protein 
concentration with lysis buffer and 3× SDS-PAGE load-
ing buffer (BioVision), and incubated at 96 °C for 5 min. 
Lysates (20 μg) were separated on 4–20 % SDS gels and 
probed with antibodies to PSMA5, PSMD1, polyubiquit-
inated proteins (clone FK1; Millipore) and β-actin (Sigma). 
Immunoblots were developed using IRDye secondary anti-
bodies and the LI-COR Odyssey scanner.
CAD5 cells
Cell pellets were re-suspended in ice-cold lysis buffer 
(1 % Triton X-100, 0.5 % sodium deoxycholate in PBS 
supplemented with benzonase (500 units per ml) and pre-
pared for SDS-PAGE as described previously [12]. Immu-
noblots were probed with the following antibodies: anti-PrP 
(ICSM35, 1:8000), anti-polyubiquitin (clone FK1, 1:1000; 
Millipore) and anti-ERK 1 and 2 (1:5000; Cell Signalling). 
Immunoblots were developed using IRDye secondary anti-
bodies and the LI-COR Odyssey scanner.
Dot blot analysis
Brain tissue was prepared as described for Western blot 
analysis, with subsequent measurement of total protein 
concentrations using the Bio-Rad Protein Assay. Samples 
were adjusted to 1 mg/ml total protein concentration with 
lysis buffer and 3× SDS-PAGE loading buffer (BioVi-
sion), and incubated at 96 °C for 5 min. Lysates (20 μg) 
were applied to a nitrocellulose membrane using Bio-Dot 
Microfiltration Apparatus (Bio-Rad), following the manu-
facturer’s instructions. The membranes were probed with 
an anti-ubiquitin antibody (clone FK1; Millipore) and ana-
lysed using the LI-COR Odyssey Infra-Red Imaging Sys-
tem, following the manufacturer’s instructions.
Data analysis
In all in vivo experiments, at least three animals per 
group were analysed and data presented as percentage 
mean ± SEM. All data analysis was performed using 
GraphPad Prism software (GraphPad Software Inc.; ver-
sion 6). Burrowing behaviour was analysed by comparing 
the percentage food pellets displaced by control and prion-
infected mice at serial time points using a mixed model 
ANOVA with Bonferroni post hoc tests. The percentages 
of UbG76V-GFP-positive cells across serial time points in 
control- and prion-infected groups were compared using 
a two-way ANOVA with Holm–Sidak-corrected post hoc 
t tests. In RNA in situ hybridisation experiments, relative 
UbG76V-GFP mRNA levels were calculated by normalis-
ing the mean UbG76V-GFP staining intensity to the mean 
staining intensity of the Actb or Gapdh control transcripts, 
and subsequently comparing control- and prion-infected 
groups using a two-tailed Student’s t test. In proteasome 
activity assays, fluorescence levels were calculated by 
measuring the mean fluorescence generated in the linear 
reaction phase across triplicate wells. To calculate specific 
proteasome catalytic activities, mean fluorescence val-
ues of epoxomicin-treated controls were subtracted from 
each sample and subsequently expressed as a percentage 
of the control group mean. Proteasome activity was com-
pared between treatment groups using a two-tailed Stu-
dent’s t test (Fig. 7a) or one-way ANOVA with Bonferroni 
post hoc tests (Fig. 7b). For proteasome subunit quantifi-
cation experiments, LI-COR scanned immunoblots were 
415Acta Neuropathol (2016) 131:411–425 
1 3
converted to grey-scale images and signal intensity com-
pared by two-tailed Student’s t tests. To compare total ubiq-
uitin levels in brain extracts of prion- and control-infected 
mice across the disease course, LI-COR scanned dot blots 
were converted to grey-scale images and signal intensities 
compared using a two-way ANOVA with Holm–Sidak-cor-
rected post hoc t tests.
Results
Progression of behavioural deficits and neuropathology 
in prion‑infected UbG76V‑GFP mice
To understand the pattern of neurodegeneration in prion-
infected UbG76V-GFP mice, groups of female mice were 
inoculated with RML prions, or uninfected control 
homogenate, at 8–10 weeks of age. Burrowing behaviour, a 
highly sensitive measure of the early effects of prion infec-
tion [6], was assessed every 3 weeks by measuring the pro-
portion of food pellets displaced from a plastic tube over-
night. The earliest evidence of burrowing impairment was 
observed at 15 weeks post-inoculation (wpi), when prion-
infected UbG76V-GFP mice displaced 60 % fewer food pel-
lets than control animals (Fig. 1). A complete loss of bur-
rowing behaviour was observed at 18 wpi, demonstrating 
the rapid nature of prion-mediated neurodegeneration. In 
accordance with animal welfare regulations, mice were 
killed at the onset of ataxia, sustained hunched posture, sig-
nificant alteration in breathing rate or loss of the righting 
reflex. The mean disease incubation time in prion-infected 
UbG76V-GFP mice was 23 wpi, with no significant differ-
ence compared to wild-type littermate controls (Fig. S1), 
confirming that disease progression was independent of the 
UbG76V-GFP transgene.
To study disease progression by neuropathology, groups 
of age-matched prion-infected and control mice were also 
culled at 8, 12 and 18 wpi. Brains were examined histologi-
cally to determine the course of neuropathological changes 
in prion-infected UbG76V-GFP mice. By 12 wpi, initial 
PrPSc deposition was observed throughout the thalamus 
and in selected regions of the cortex and hypothalamus of 
prion-infected mice (Fig. 2). Less intense, diffuse immu-
nostaining was visualised in regions of the midbrain and 
brainstem. By 18 wpi, PrPSc accumulation became more 
pronounced in these regions, with evidence of spread to the 
cerebellum. By end-stage disease at 23 wpi, dense PrPSc 
deposition was detectable in all brain regions examined. 
No differences in the spatiotemporal pattern of PrPSc dis-
tribution were observed between prion-inoculated UbG76V-
GFP mice and their wild-type littermates. As reported 
previously, the thalamus displayed robust PrPSc accumula-
tion at early stages of disease [33]. As a result, this brain 
region was selected for phenotype analysis in subsequent 
experiments.
Regional deposition of PrPSc is known to be a strong 
inducer of reactive astrocytosis, characterised by the accu-
mulation of GFAP, cytoplasmic hypertrophy and the pro-
trusion of long processes into the surrounding interstitium 
[11]. Quantification of GFAP-labelled cells in the thalamus 
revealed progressive reactive astrocytosis in prion-infected 
mice from 12 wpi (Fig. 3a, b). Spongiform vacuolation of 
the neuropil, a classical histological feature of prion dis-
ease, was observed in the thalamus from 18 wpi (Fig. S2). 
Histological analysis of NeuN-labelled cells revealed a 
50 % reduction in neuronal density in the thalamus at end-
stage disease, coincident with the onset of terminal motor 
signs (Fig. 3c, d).
UbG76V‑GFP reporter accumulates early 
in prion‑infected mice
To determine the functional status of the UPS at each stage 
of disease progression, UbG76V-GFP levels were assessed 
by anti-GFP immunofluorescent staining. Within the time 
window of the present study, no age-related impairment of 
the UPS was observed since numbers of GFP-positive cells 
remained persistently low in control-inoculated mice. A 
progressive increase in UbG76V-GFP levels was observed in 
the thalamus of prion-infected mice from 12 wpi (Fig. 4). 
Fig. 1  Prion-infected UbG76V-GFP reporter mice display sudden 
decline in burrowing behaviour from 15 wpi. UbG76V-GFP reporter 
mice were inoculated with 30 μl of 1 % RML prion-infected brain 
homogenate or 1 % uninfected brain homogenate at 8–10 weeks 
of age. Burrowing behaviour was assessed by measuring the per-
centage of food pellets displaced from a plastic burrow placed in 
single-housed cages overnight. Significant impairment of burrow-
ing behaviour was observed from 15 wpi in prion-infected animals 
(blue line) versus uninfected controls (grey line). Data are percentage 
mean ± SEM (***p < 0.001; mixed model ANOVA with Bonferroni 
post hoc tests; n = 9 per group)
416 Acta Neuropathol (2016) 131:411–425
1 3
UbG76V-GFP reporter accumulation was also observed in 
other brain regions affected by PrPSc deposition (Fig. S3); 
however, subsequent phenotype analysis focussed on the 
thalamus due to the robust PrPSc accumulation observed 
at early disease stages (Fig. 2). To identify which cell 
populations were affected by UPS dysfunction, we double-
labelled cells with specific marker antibodies for the dif-
ferent neural cell populations. A significant increase in the 
percentage of GFP-positive neurons was observed in the 
thalamus of prion-infected mice at 12 wpi (Fig. 5a, c). This 
preceded the onset of burrowing behaviour deficits and 
coincided with the first appearance of astrocytosis. By 18 
wpi, this proportion had increased, with 40 % of neurons 
displaying accumulation of the GFP reporter. By end-stage 
disease, a large amount of variation in the percentage of 
GFP-positive neurons was observed in prion-infected mice. 
This could indicate variation in the recognition of end-stage 
prion disease based on current phenotypic criteria or reflect 
the significant neuronal loss observed at this time point.
In addition to evidence of neuronal UPS dysfunc-
tion, marked accumulation of the GFP reporter was also 
observed in the reactive astrocytes of prion-infected mice 
(Fig. 5b, d). At 12 wpi, 47 % of GFAP-labelled astrocytes 
were identified as GFP-positive. This proportion increased 
dramatically to more than 86 % of reactive astrocytes by 
18 wpi. Dual immunofluorescence staining of GFP and 
Fig. 2  PrPSc distribution in brains of prion-infected UbG76V-GFP 
mice and wild-type littermates. UbG76V-GFP mice were inoculated 
with 30 μl of 1 % RML prion-infected brain homogenate or 1 % 
uninfected brain homogenate (control) between 8 and 10 weeks of 
age. Animals were culled at 8, 12, 18 and 23 wpi. To control for the 
presence of the UbG76V-GFP transgene, an additional group of wild-
type littermates received RML prion inocula. Staining of formic acid 
treated sections reveals intense PrPSc immunostaining from 12 wpi 
with widespread distribution in the thalamus and focal regions of the 
cortex. A similar spatiotemporal pattern of PrPSc accumulation was 
observed in all prion-infected animals, independent of genotype. Data 
are representative of n = 4 mice per group
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the microglial marker Iba1 revealed no evidence of GFP-
reporter accumulation in microglia at any time point 
investigated.
Interestingly, a reduction in the proportion of GFP-pos-
itive neurons and astrocytes was observed at end-stage dis-
ease. While the reason for this trend remains unclear, one 
possible explanation is translational repression secondary 
to sustained activation of the unfolded protein response in 
prion-infected mice [34]. This could reduce the propor-
tion of GFP-positive cells by reducing de novo synthesis of 
UbG76V-GFP protein and by reducing the burden of improp-
erly folded nascent proteins targeted to the proteasome via 
the ERAD pathway.
To demonstrate that the accumulation of the UbG76V-
GFP protein was a result of impaired protein degrada-
tion rather than increased protein synthesis, we measured 
UbG76V-GFP transcript levels by RNA in situ hybridisation 
at 18 wpi, when accumulation of the UbG76V-GFP protein is 
well established and anatomically widespread (Fig. S4). No 
differences in UbG76V-GFP transcript levels were observed 
in the thalamus of control and prion-infected UbG76V-GFP 
reporter mice at 18 wpi, confirming that the increase in 
UbG76V-GFP protein levels in diseased animals is due to 
impaired degradation of the reporter rather than elevation/
stabilisation of the UbG76V-GFP transcript.
Fig. 3  Reactive astrocyto-
sis and neuronal loss in the 
thalamus of prion-infected 
UbG76V-GFP reporter mice. 
UbG76V-GFP reporter mice 
were inoculated with 30 μl of 
1 % RML prion-infected brain 
homogenate or 1 % uninfected 
brain homogenate (control) 
between 8 and 10 weeks of age 
(n = 3–4 per group). Animals 
were culled at 8, 12, 18 and 23 
wpi. a Anti-GFAP immuno-
fluorescent staining (cyan) of 
frozen sections reveals reactive 
astrocytosis at 12 wpi in the 
thalamus. b Quantification 
of GFAP-labelled cells in the 
thalamus of control (grey bars) 
and prion-infected (blue bars) 
UbG76V-GFP mice. Extensive 
proliferation of reactive astro-
cytes is observed from 12 wpi. c 
Anti-NeuN immunofluorescent 
staining (red) of frozen sections 
reveals marked neuronal loss 
at 23 wpi. d Quantification 
of NeuN-labelled cells in the 
thalamus of control (grey bars) 
and prion-infected (blue bars) 
UbG76V-GFP mice. A significant 
reduction in neuronal density 
is observed at 23 wpi. Data are 
mean ± SEM (***p < 0.001; 
two-way ANOVA with 
Holm Sidak-corrected post 
hoc t tests). Scale bar in a, 
c = 40 μm. Nuclei were stained 
with DAPI (blue)
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Accumulation of polyubiquitinated conjugates 
in neurons of prion‑infected mice
To investigate whether observed UPS dysfunction is asso-
ciated with impaired substrate clearance, we conducted a 
dot blot analysis of polyubiquitinated conjugate levels in 
brains of prion-infected and uninfected control mice at dif-
ferent stages of disease progression (Fig. S5). This experi-
ment was performed using brain tissue from wild-type 
mice, to allow comparison of endogenous UPS substrate 
levels, independently from the polyubiquitinated UbG76V-
GFP reporter. A significant increase in levels of polyubiq-
uitinated conjugates was observed from 18 wpi in prion-
infected animals (Fig. 6a). These findings were confirmed 
by anti-polyubiquitin western blot of thalamic tissue from 
control and prion-inoculated UbG76V-GFP reporter mice 
(Fig. 6b). Densitometry revealed a 53 % increase in levels 
of high molecular weight (MW) polyubiquitinated conju-
gates in prion-infected UbG76V-GFP reporter mice. Subse-
quent immunofluorescence staining of frozen brain sections 
revealed localised deposition of polyubiquitin in thalamic 
neurons of prion-infected UbG76V-GFP reporter mice at 
end-stage disease (Fig. 6c). Taken together, these observa-
tions demonstrate that observed UPS impairment is asso-
ciated with marked disruption of neuronal proteostasis in 
prion-infected UbG76V-GFP reporter mice.
Interestingly, UbG76V-GFP reporter accumulation was 
only observed in neurons with high levels of polyubiquitin 
staining (Fig. 6c). This suggests a possible discrepancy in 
the detection sensitivity of the UbG76V-GFP reporter versus 
polyubiquitin. Alternatively, the accumulation of poly-
ubiquitin in the absence of UbG76V-GFP in some neurons 
may indicate prion-mediated disruption of non-proteolytic 
pathways which are also regulated by post-translational 
polyubiquitination.
Impairment of proteasome catalytic activity 
in prion‑infected mice
To examine whether observed UPS dysfunction could 
be attributed to impairment of the proteasome itself, we 
compared proteasome catalytic activities in control and 
prion-inoculated UbG76V-GFP reporter mice at early 
and late stages of disease progression. Catalytic turno-
ver by the three peptidase sites of the 20S proteasome 
was measured by comparing the rates of hydrolysis of 
specific fluorogenic peptides in homogenised thalamic 
tissue. At 12 wpi, no significant differences in chymot-
rypsin-, caspase- or trypsin-like activities were observed 
(Fig. 7a, Fig. S6). Since only 21 % of thalamic neurons 
displayed UbG76V-GFP reporter accumulation at this early 
disease stage (Fig. 5c), it is likely that measurement of 
total proteasome activity in a crude thalamic homogen-
ate lacked the sensitivity to detect catalytic impairment 
in the small subpopulation of affected cells. We therefore 
also measured proteasome catalytic activities at 18 wpi, 
when UbG76V-GFP reporter accumulation was more ana-
tomically widespread throughout the thalamus (Fig. 4). 
At this stage, we observed a 27 % reduction in the activ-
ity of the chymotrypsin-like site in the thalamus of 
Fig. 4  Early accumulation of the UbG76V-GFP reporter in prion-
infected mice. UbG76V-GFP reporter mice were inoculated with 30 μl 
of 1 % RML prion-infected brain homogenate or 1 % uninfected 
brain homogenate (control) between 8 and 10 weeks of age (n = 3–4 
per group). Animals were culled at 8, 12, 18 and 23 wpi. Prion pro-
tein staining of formic acid treated sections reveals PrPSc immu-
nostaining from 12 wpi in thalamus. Immunofluorescent staining of 
frozen sections with anti-GFP antibody reveals progressive accumu-
lation of UbG76V-GFP reporter from 12 wpi. UbG76V-GFP reporter 
levels remained unchanged in age-matched uninfected control mice. 
Scale bar 40 μm
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prion-infected mice (Fig. 7a). No evidence of impairment 
was observed for caspase- or trypsin-like sites in the 
disease condition (Fig. S6). Impairments in proteasome 
peptidase activity could be masked by a compensatory 
increase in the total number of proteasomes. To confirm 
that the size of the proteasome pool remained unaltered 
in prion-infected mice, levels of two key constitutive pro-
teasome subunits were measured by western blot. At 18 
wpi, levels of PSMD1, a subunit of the 19S regulatory 
particle and PSMA5, a subunit of the 20S proteasome, 
were unaltered in the thalamus of prion-infected mice 
(Fig. S7). Collectively, these results suggest that there is 
selective inhibition of the chymotrypsin-like site of the 
proteasome in prion-infected mice, independent of any 
overall changes in proteasome number.
Proteasome activator IU1 reduces levels 
of polyubiquitinated conjugates and PrPSc 
in prion‑infected cells
To test whether up-regulation of proteasome activity could 
facilitate clearance of the backlog of polyubiquitinated con-
jugates observed in the present study, we tested the effect of 
the small molecule Usp14 inhibitor IU1 in prion-infected 
CAD5 neuronal cells. Infection of CAD5 cells with RML 
prions resulted in a modest decrease in proteasome activ-
ity (Fig. 7b), consistent with previously described observa-
tions in PK1 cells and prion-infected UbG76V-GFP mice [24]. 
Treatment of prion-infected CAD5 cells with the proteasome 
inhibitor lactacystin resulted in increased levels of polyubiq-
uitinated conjugates (Fig. 7c) and further accumulation of 
Fig. 5  UbG76V-GFP reporter accumulates in neurons and astrocytes 
of prion-infected mice. UbG76V-GFP reporter mice were inoculated 
with 30 μl of 1 % RML prion-infected brain homogenate or 1 % 
uninfected brain homogenate (control) between 8 and 10 weeks of 
age (n = 3–4 per group). Animals were culled at 8, 12, 18 and 23 
wpi. a Comparison of immunofluorescent staining with anti-GFP 
and anti-NeuN antibodies in thalamus of prion-infected UbG76V-GFP 
reporter mice at 8 wpi versus 18 wpi. Scale bar 3.75 μm. b Com-
parison of immunofluorescent staining with anti-GFP and anti-GFAP 
antibodies in thalamus of prion-infected UbG76V-GFP reporter mice 
at 8 wpi versus 18 wpi. Scale bar 6.5 μm. c Quantification of GFP 
levels in NeuN-labelled cells of uninfected (grey bars) and prion-
infected (blue bars) UbG76V-GFP mice. UbG76V-GFP reporter accu-
mulates in a subset of neurons from 12 wpi. d Quantification of GFP 
levels in GFAP-labelled cells of uninfected (grey bars) and prion-
infected (blue bars) UbG76V-GFP mice. UbG76V-GFP reporter accu-
mulates in astrocytes from 12 wpi. Data are percentage mean ± SEM 
(*p < 0.05; **p < 0.01;***p < 0.001; two-way ANOVA with Holm–
Sidak-corrected post hoc t tests)
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PrPSc (Fig. 7d). This could be attributed to a small rise in lev-
els of PrPC substrate or impaired clearance of misfolded PrP 
conformers in lactacystin-treated cells. In contrast, activation 
of the proteasome by treatment with the Usp14 inhibitor IU1 
(Fig. 7b), decreased levels of polyubiquitinated conjugates 
(Fig. 7c) and resulted in a marked reduction in PrPSc load 
(Fig. 7d). Importantly, these effects were reversed by the 
inclusion of lactacystin, verifying that the action of IU1 is 
dependent upon proteasome activity. As expected, combined 
lactacystin and IU1 treatment increased total polyubiquit-
inated protein content, consistent with the inhibition of de-
ubiquitinase Usp14 by IU1. Taken together, these findings 
suggest that the proteasome plays an important role in the 
clearance of polyubiquitinated conjugates and regulation of 
PrPSc levels in prion-infected neuronal cells.
Discussion
In the present study, we identify functional impairment 
of the UPS as an early feature of prion disease patho-
genesis, preceding the onset of behavioural dysfunction 
and neuronal loss. Progressive UPS impairment in neu-
ronal and astrocytic cell populations was accompanied by 
marked accumulation of polyubiquitinated conjugates. 
Consistent with a role of UPS dysfunction in prion dis-
ease pathogenesis, pharmacological activation of the UPS 
in prion-infected cultured cells facilitated clearance of 
polyubiquitinated conjugates and reduced total levels of 
PrPSc. Taken together, these findings identify the UPS as an 
important target in the development of therapeutics for the 
treatment of prion diseases.
Fig. 6  Polyubiquitinated conjugates accumulate in brains of prion-
infected mice. a Dot blot quantification of polyubiquitinated con-
jugate levels in whole brain homogenates of prion-infected (blue 
bars) and control-inoculated (grey bars) wild-type mice. Original 
dot blot image shown in Fig. S5. Data are normalised to β-actin 
expression and expressed as mean ± SEM (n = 4 per group; 
**p < 0.01;***p < 0.001; two-way ANOVA with Holm–Sidak-cor-
rected post hoc t tests). b Thalamic tissue from prion-infected and 
uninfected control UbG76V-GFP mice at 23 wpi was homogenised and 
analysed by anti-polyubiquitin western blot (clone FK1). Densitom-
etry revealed a 53 % increase in levels of high MW polyubiquitinated 
conjugates (>100 kDa) in prion-infected UbG76V-GFP mice, com-
pared with uninfected controls when normalised to the β-actin house-
keeping gene (p < 0.01; two-tailed Student’s t test; n = 5 per group). 
c Frozen brain sections from prion-infected and uninfected control 
mice at 23 wpi were stained with anti-polyubiquitin (red), anti-GFP 
(green) and anti-β-III-tubulin (white) antibodies. Prion-infected mice 
show increased levels of UbG76V-GFP reporter and polyubiquitin 
staining in β-III-tubulin-positive neurons. Scattered polyubiquitin-
positive puncta are seen throughout the neuropil in prion-infected 
mice. Scale bar 10 μm
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Impairment of the UPS is likely to have pleiotropic 
effects in the prion-infected brain, which together could 
contribute to progressive neurotoxicity, synaptic dysfunc-
tion and ultimately cell death [31]. Previous studies of 
murine scrapie reported that early impairment of burrow-
ing behaviour is coincident with a marked decline in levels 
of pre- and post-synaptic proteins [5, 16, 34]. Mallucci and 
colleagues identified that this synaptic failure correlated 
with sustained translational repression of global protein 
synthesis by eIF2α-P, a key mediator of the unfolded pro-
tein response (UPR; Moreno et al. [34]). Precipitant ER 
stress was attributed to rising levels of misfolded PrP in the 
ER. In the present study, neuronal UPS impairment pre-
ceded the earliest behavioural signs of synaptic dysfunc-
tion, suggesting that UPR activation may also arise from 
reduced clearance of ubiquitinated substrates by the ER-
associated protein degradation (ERAD) pathway and asso-
ciated accumulation of non-native proteins in the ER.
Fig. 7  Measurement of 26S proteasome activity in prion-infected 
UbG76V-GFP reporter mice and ScCAD5 cells. a UbG76V-GFP reporter 
mice were inoculated with 30 μl of 1 % RML prion-infected brain 
homogenate or 1 % uninfected brain homogenate (control) and 
culled at 12 wpi or 18 wpi. Thalamic tissue was homogenised and 
chymotrypsin-like activity assessed by measuring fluorescence gen-
erated from cleavage of a site-specific peptide substrate, adjusted to 
an epoxomicin-treated control. Data are percentage mean ± SEM, 
expressed relative to control (n = 5 per group). A significant impair-
ment in chymotrypsin-like activity was observed in prion-infected 
mice at 18 wpi (*p < 0.05; two-tailed Student’s t test). No significant 
difference in caspase- or trypsin-like activities was observed (Fig. 
S6). b–d Prion-infected (ScCAD5) and uninfected control (CAD5) 
cells were treated with either 1 μM lactacystin (Lac), 50 μM IU1 
(IU1), 1 μM lactacystin and 50 μM IU1 (Lac/IU1), or DMSO vehicle 
alone (-) for 16 h. An equal concentration of 0.5 % DMSO vehicle 
was used in all cultures. b Cell lysates were collected and chymot-
rypsin-like proteasome activity analysed by fluorogenic assay. Data 
are percentage mean ± SEM, expressed relative to CAD5 vehicle-
only (-) control (n = 4 per group). Prion infection results in a modest 
decrease in proteasome activity, which is reversed by IU1 (*p < 0.05; 
one-way ANOVA with Bonferroni post hoc tests). c Cell lysates were 
analysed by immunoblotting with anti-polyubiquitin antibody (FK1). 
ERK1/2 was used as a loading control. Changes in polyubiquitin lev-
els are closely related to underlying proteasome activity. Combined 
lactacystin and IU1 treatment increased polyubiquitinated protein 
content, consistent with the inhibition of de-ubiquitinase USP14 by 
IU1. d Cell lysates were collected and equal quantities analysed by 
immunoblotting with anti-PrP antibodies (untreated or following 
limited proteinase K digestion to reveal PrPSc). Inhibition of the pro-
teasome results in accumulation of PrPSc; stimulation of proteasome 
activity reduces PrPSc load in ScCAD5 cells
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In addition to disruption of cellular proteostasis, UPS 
dysfunction may lead to neurotoxicity through activation 
of pro-apoptotic pathways. In cellular models of prion dis-
ease, intra-neuronal prion propagation in the presence of 
mild proteasome inhibition triggered formation of cytosolic 
aggresomes containing vimentin, PrPSc, hsp70, ubiqui-
tin and proteasome subunits [8, 25]. The PrPSc aggresome 
formation was temporally associated with caspase 3 and 8 
activation, triggering neuronal apoptosis [25]. Interestingly, 
abrogation of aggresome formation with microtubule inhib-
itors prevented apoptosis, suggesting that the sequestration 
of key components of the cellular protein quality control 
machinery may induce neurotoxicity through depletion of 
functional soluble pools and/or the formation of insoluble 
protein aggregates. Co-precipitation of vimentin and PrPSc 
in the brains of prion-infected mice suggest that similar 
aggresome-like structures may also be present in vivo [25]. 
Together with evidence of early neuronal UPS dysfunction 
described in the present study, these observations indicate 
that impairment of the UPS may promote neuronal apopto-
sis in regions worst affected by prion pathology.
Despite early occurrence of UPS dysfunction in thalamic 
neurons in the present study, significant neuronal loss was 
not observed until end-stage disease (Fig. 3c). This appar-
ent discrepancy could be accounted for by the compensa-
tory induction of other protein quality control systems. 
For example, the accumulation of autophagic vacuoles has 
been described in neurons of scrapie-infected hamsters and 
in synapses of human CJD and FFI patients [2, 36]. More 
recently, Xu and colleagues reported that late-stage acti-
vation of the macroautophagic system in scrapie-infected 
hamsters was associated with a reduction in the levels of 
polyubiquitinated protein conjugates and the macroau-
tophagy substrate sequestosome 1 [44]. Compensatory 
up-regulation of macroautophagy may help to reduce pro-
teotoxic stress in neurons with UPS dysfunction, resulting 
in a more protracted disease course and delayed onset of 
neuronal loss.
In addition to the neuronal cell population, we observed 
marked accumulation of the UbG76V-GFP reporter in sur-
rounding reactive astrocytes. Despite apparent disruption 
to cellular proteostasis, extensive astrocyte proliferation 
was observed across the disease course, with no evidence 
of a reduction in astrocyte counts at end-stage disease. The 
relative resistance of astrocytes to the cytotoxic effects of 
proteasome impairment has been reported by numerous 
studies [10, 21, 32, 40, 46], indicating that astrocytes may 
have well adapted protein quality control pathways to com-
pensate for UPS failure. A recent study of scrapie infection 
in hamsters reported a selective increase in αβ-crystallin 
expression in astrocytes [43]. Similar observations were 
reported in regions of severe pathology in human CJD 
and FFI post-mortem brain tissue [43]. Thus, the efficient 
induction of heat shock response genes in astrocytes may 
account for their apparent resistance to high levels of UPS 
dysfunction in the present model.
The aetiology of UPS dysfunction in the brains of prion-
infected mice could partly be attributed to a reduction in 
activity of the 26S proteasome. Inhibition of chymotrypsin- 
and caspase-like activities was previously identified in the 
brains of RML and ME7 prion-infected mice at end-stage 
disease [22, 24]. Subsequent in vitro studies suggested that 
misfolded PrP isoforms inhibit proteolytic activity by stabi-
lising the closed conformation of the substrate entry chan-
nel [7]. To interact with the proteasome, a cytosolic form 
of PrPSc must be present in brains of prion-infected mice. 
The existence of such a species is supported by evidence 
of PrPSc and proteasome colocalisation in perinuclear 
aggresomes in prion-infected neuroblastoma cells [25] and 
co-immunoprecipitation of PrPSc with vimentin [25] and 
subunits of the 26S proteasome [7] in prion-infected mouse 
brains. The trafficking pathway by which PrSc gains access 
to the cytosolic compartment remains the focus of ongoing 
research (reviewed in [13]).
In the present study, we measured proteasome catalytic 
activities in the thalamus 5 weeks before end-stage dis-
ease, when a maximal proportion of neurons and astrocytes 
displayed UbG76V-GFP reporter accumulation (Fig. 5). 
Selective impairment of chymotrypsin-like activity was 
observed, in the absence of any detectable change in the 
caspase- or trypsin-like sites. Whilst previous in vitro stud-
ies have suggested that simultaneous inhibition of multiple 
catalytic activities is required to disrupt proteasome func-
tion [23], it remains unclear whether impairment of a single 
activity is sufficient to have detrimental effect in the con-
text of protein-misfolding disorders. In addition to impair-
ment of 26S proteasome catalytic activity, UPS dysfunction 
observed in the present study could be attributed to protea-
somal insufficiency [29], whereby ongoing prion propaga-
tion could overwhelm the capacity of the proteasome to 
clear misfolded protein substrates arising from errors in 
translation or co-translational folding.
To establish whether enhancement of proteasome activ-
ity could promote clearance of the backlog of polyubiqui-
tinated conjugates, we tested the effect of the small mol-
ecule inhibitor IU1 in prion-infected CAD5 (ScCAD5) 
neuronal cells. Upon RML prion infection, these cells dis-
play impairment of chymotrypsin-like proteasome activity 
and accumulation of polyubiquitinated conjugates, mirror-
ing observations in prion-infected UbG76V-GFP reporter 
mice. IU1 has previously been shown to enhance protea-
some activity by inhibiting ubiquitin chain trimming medi-
ated by the proteasome-associated deubiquitinating enzyme 
Usp14 [27]. Suppression of chain trimming is thought to 
stabilise ubiquitinated substrates on the proteasome and 
promote their unfolding and translocation into the 20S 
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core particle for degradation. We observed that treatment 
of ScCAD5 cells with IU1 led to a reduction in levels of 
polyubiquitinated conjugates, suggesting that UPS up-regu-
lation is sufficient to reduce levels of potentially toxic ubiq-
uitinated proteins which accumulate in prion infection.
Furthermore, stimulation of UPS activity was sufficient 
to reduce cellular levels of PrPSc. Consistent with previous 
reports in prion-infected N2a cells [17], we observed that 
IU1 treatment resulted in a significant reduction in PrPC 
levels in ScCAD5 cells (Fig. 7d). Whilst the major route of 
PrPC degradation is considered to be the endosomal/lysoso-
mal pathway [15], a subpopulation of PrPC is also known to 
be degraded by ER-associated degradation (ERAD), prior 
to its release into the secretory pathway [30, 45]. Activa-
tion of the proteasome as the final step of the ERAD path-
way could therefore account for reduced PrPC levels in 
IU1-treated ScCAD5 cells. This depletion of PrPC could 
partly account for the marked reduction in PrPSc load in 
IU1-treated ScCAD5 cells, due to a reduction in the rate of 
ongoing prion conversion. In addition, proteasome activa-
tion by IU1 may facilitate increased clearance of misfolded 
PrPSc conformers, which we recently identified as likely 
substrates of the UPS [12].
The dual effect of proteasome activation on clearance of 
polyubiquitinated conjugates and reduction in PrPSc load is 
likely to reduce proteotoxic stress in prion-infected cells. 
Since immortalised cell lines such as the CAD5 cells used 
in the present study do not display prion-induced cell death, 
they cannot accurately model in vivo cytotoxicity observed 
in prion-infected mice. To establish whether UPS activa-
tion has a beneficial impact on rates of prion propagation 
and disease incubation time, it will therefore be necessary 
to test novel proteasome activator compounds in vivo. A 
recent study by Wilson and colleagues did not observe evi-
dence of altered proteasome activity upon IU1 administra-
tion in wild-type mice [41]. This highlights the significant 
challenge faced in the development of pharmacological 
compounds to enhance UPS activity in vivo.
In this study, we have demonstrated that impairment of 
the UPS precedes the development of early behavioural 
symptoms and, more importantly, neuronal loss in prion-
infected mice. Early intervention to compensate for accu-
mulation of misfolded proteins by induction of protein 
catabolism may halt the progressive neurotoxicity observed 
in prion disease. In the absence of therapies to upregulate 
the UPS, the development of pharmacological compounds 
that stimulate UPS activity and are capable of crossing the 
blood–brain barrier remains a research priority.
Acknowledgments We thank Jayne Holby, Michael Brown, Sarah 
Lyall and Caroline Powell for their technical support. This study was 
supported financially by the Medical Research Council. CM was 
in receipt of a UCLH Comprehensive Biomedical Research Cen-
tre MBPhD studentship. Work performed by SB was undertaken at 
UCLH/UCL who received a proportion of funding from the Depart-
ment of Health’s NIHR Biomedical Research Centre’s funding 
scheme. ZO and JJL’s contributions were supported by the Spanish 
Ministry of Science MICINN/MINECO.
Compliance with ethical standards 
Ethical approval Work with animals was performed in accord-
ance with a licence approved and granted by the UK Home Office 
(PPL70/7274) and conformed to University College London institu-
tional and ARRIVE guidelines. All experiments involving animals 
were approved by the MRC Prion Unit Ethics Committee.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Ang XL, Seeburg DP, Sheng M, Harper JW (2008) Regulation 
of postsynaptic RapGAP SPAR by Polo-like kinase 2 and the 
SCFbeta-TRCP ubiquitin ligase in hippocampal neurons. J Biol 
Chem 283:29424–29432. doi:10.1074/jbc.M802475200
 2. Boellaard JW, Kao M, Schlote W, Diringer H (1991) Neuronal 
autophagy in experimental scrapie. Acta Neuropathol (Berl) 
82:225–228
 3. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, 
Graham RLJ, Hess S, Chan DC (2011) Broad activation of the 
ubiquitin-proteasome system by Parkin is critical for mitophagy. 
Hum Mol Genet 20:1726–1737. doi:10.1093/hmg/ddr048
 4. Cronier S, Gros N, Tattum MH, Jackson GS, Clarke AR, 
Collinge J, Wadsworth JDF (2008) Detection and characteriza-
tion of proteinase K-sensitive disease-related prion protein with 
thermolysin. Biochem J 416:297–305. doi:10.1042/BJ20081235
 5. Cunningham C, Deacon R, Wells H, Boche D, Waters S, Diniz 
CP, Scott H, Rawlins JNP, Perry VH (2003) Synaptic changes 
characterize early behavioural signs in the ME7 model of murine 
prion disease. Eur J Neurosci 17:2147–2155
 6. Deacon RM, Raley JM, Perry VH, Rawlins JN (2001) Burrowing 
into prion disease. NeuroReport 12:2053–2057
 7. Deriziotis P, André R, Smith DM, Goold R, Kinghorn KJ, 
Kristiansen M, Nathan JA, Rosenzweig R, Krutauz D, Glick-
man MH, Collinge J, Goldberg AL, Tabrizi SJ (2011) Mis-
folded PrP impairs the UPS by interaction with the 20S protea-
some and inhibition of substrate entry. EMBO J 30:3065–3077. 
doi:10.1038/emboj.2011.224
 8. Dron M, Dandoy-Dron F, Farooq Salamat MK, Laude H (2009) 
Proteasome inhibitors promote the sequestration of PrPSc into 
aggresomes within the cytosol of prion-infected CAD neuronal 
cells. J Gen Virol 90:2050–2060. doi:10.1099/vir.0.010082-0
 9. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome 
proteolytic pathway: destruction for the sake of construction. 
Physiol Rev 82:373–428. doi:10.1152/physrev.00027.2001
 10. Goldbaum O, Vollmer G, Richter-Landsberg C (2006) Protea-
some inhibition by MG-132 induces apoptotic cell death and 
mitochondrial dysfunction in cultured rat brain oligodendrocytes 
but not in astrocytes. Glia 53:891–901. doi:10.1002/glia.20348
 11. Gomi H, Yokoyama T, Fujimoto K, Ikeda T, Katoh A, Itoh T, Ito-
hara S (1995) Mice devoid of the glial fibrillary acidic protein 
424 Acta Neuropathol (2016) 131:411–425
1 3
develop normally and are susceptible to scrapie prions. Neuron 
14:29–41
 12. Goold R, McKinnon C, Rabbanian S, Collinge J, Schiavo G, 
Tabrizi SJ (2013) Alternative fates of newly formed PrPSc 
upon prion conversion on the plasma membrane. J Cell Sci. 
doi:10.1242/jcs.120477
 13. Goold R, McKinnon C, Tabrizi SJ (2015) Prion degradation 
pathways: potential for therapeutic intervention. Mol Cell Neu-
rosci 66:12–20. doi:10.1016/j.mcn.2014.12.009
 14. Goold R, Rabbanian S, Sutton L, Andre R, Arora P, Moonga J, 
Clarke AR, Schiavo G, Jat P, Collinge J, Tabrizi SJ (2011) Rapid 
cell-surface prion protein conversion revealed using a novel cell 
system. Nat Commun 2:281. doi:10.1038/ncomms1282
 15. Grassmann A, Wolf H, Hofmann J, Graham J, Vorberg I (2013) 
Cellular aspects of prion replication in vitro. Viruses 5:374–405. 
doi:10.3390/v5010374
 16. Hilton KJ, Cunningham C, Reynolds RA, Perry VH (2013) Early 
hippocampal synaptic loss precedes neuronal loss and associates 
with early behavioural deficits in three distinct strains of prion 
disease. PLoS One 8:e68062. doi:10.1371/journal.pone.0068062
 17. Homma T, Ishibashi D, Nakagaki T, Fuse T, Mori T, Satoh 
K, Atarashi R, Nishida N (2015) Ubiquitin-specific protease 
14 modulates degradation of cellular prion protein. Sci Rep 
5:11028. doi:10.1038/srep11028
 18. Hori O, Ichinoda F, Yamaguchi A, Tamatani T, Taniguchi M, 
Koyama Y, Katayama T, Tohyama M, Stern DM, Ozawa K, Kitao 
Y, Ogawa S (2004) Role of Herp in the endoplasmic reticulum 
stress response. Genes Cells Devoted Mol Cell Mech 9:457–469. 
doi:10.1111/j.1356-9597.2004.00735.x
 19. Hung AY, Sung CC, Brito IL, Sheng M (2010) Degradation 
of postsynaptic scaffold GKAP and regulation of dendritic 
spine morphology by the TRIM3 ubiquitin ligase in rat hip-
pocampal neurons. PLoS One 5:e9842. doi:10.1371/journal.
pone.0009842
 20. Ironside JW, McCardle L, Hayward PA, Bell JE (1993) Ubiqui-
tin immunocytochemistry in human spongiform encephalopa-
thies. Neuropathol Appl Neurobiol 19:134–140
 21. Kahana S, Finniss S, Cazacu S, Xiang C, Lee H-K, Brodie S, 
Goldstein RS, Roitman V, Slavin S, Mikkelsen T, Brodie C 
(2011) Proteasome inhibitors sensitize glioma cells and glioma 
stem cells to TRAIL-induced apoptosis by PKCε-dependent 
downregulation of AKT and XIAP expressions. Cell Signal 
23:1348–1357. doi:10.1016/j.cellsig.2011.03.017
 22. Kang S-C, Brown DR, Whiteman M, Li R, Pan T, Perry G, Wis-
niewski T, Sy M-S, Wong B-S (2004) Prion protein is ubiquit-
inated after developing protease resistance in the brains of scra-
pie-infected mice. J Pathol 203:603–608. doi:10.1002/path.1555
 23. Kisselev AF, Callard A, Goldberg AL (2006) Importance of 
the different proteolytic sites of the proteasome and the effi-
cacy of inhibitors varies with the protein substrate. J Biol Chem 
281:8582–8590. doi:10.1074/jbc.M509043200
 24. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, 
Naumann H, Clarke AR, van Leeuwen FWB, Menéndez-Benito 
V, Dantuma NP, Portis JL, Collinge J, Tabrizi SJ (2007) Disease-
associated prion protein oligomers inhibit the 26S proteasome. 
Mol Cell 26:175–188. doi:10.1016/j.molcel.2007.04.001
 25. Kristiansen M, Messenger MJ, Klöhn P-C, Brandner S, Wads-
worth JDF, Collinge J, Tabrizi SJ (2005) Disease-related prion 
protein forms aggresomes in neuronal cells leading to cas-
pase activation and apoptosis. J Biol Chem 280:38851–38861. 
doi:10.1074/jbc.M506600200
 26. Lee A-H, Iwakoshi NN, Anderson KC, Glimcher LH (2003) 
Proteasome inhibitors disrupt the unfolded protein response in 
myeloma cells. Proc Natl Acad Sci 100:9946–9951. doi:10.1073/
pnas.1334037100
 27. Lee B-H, Lee MJ, Park S, Oh D-C, Elsasser S, Chen P-C, 
Gartner C, Dimova N, Hanna J, Gygi SP, Wilson SM, King RW, 
Finley D (2010) Enhancement of proteasome activity by a small-
molecule inhibitor of USP14. Nature 467:179–184. doi:10.1038/
nature09299
 28. Lindsten K, Menéndez-Benito V, Masucci MG, Dantuma NP 
(2003) A transgenic mouse model of the ubiquitin/proteasome 
system. Nat Biotechnol 21:897–902. doi:10.1038/nbt851
 29. Lobanova ES, Finkelstein S, Skiba NP, Arshavsky VY (2013) 
Proteasome overload is a common stress factor in multiple forms 
of inherited retinal degeneration. Proc Natl Acad Sci 110:9986–
9991. doi:10.1073/pnas.1305521110
 30. Ma J, Lindquist S (2001) Wild-type PrP and a mutant associated 
with prion disease are subject to retrograde transport and protea-
some degradation. Proc Natl Acad Sci USA 98:14955–14960. 
doi:10.1073/pnas.011578098
 31. McKinnon C, Tabrizi SJ (2014) The ubiquitin-proteasome sys-
tem in neurodegeneration. Antioxid Redox Signal 21:2302–
2321. doi:10.1089/ars.2013.5802
 32. Middeldorp J, Kamphuis W, Sluijs JA, Achoui D, Leenaars 
CHC, Feenstra MGP, van Tijn P, Fischer DF, Berkers C, Ovaa 
H, Quinlan RA, Hol EM (2009) Intermediate filament transcrip-
tion in astrocytes is repressed by proteasome inhibition. FASEB 
J Off Publ Fed Am Soc Exp Biol 23:2710–2726. doi:10.1096/
fj.08-127696
 33. Mirabile I, Jat PS, Brandner S, Collinge J (2015) Identification 
of clinical target areas in the brainstem of prion-infected mice. 
Neuropathol Appl Neurobiol. doi:10.1111/nan.12189
 34. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Mar-
tin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett 
DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci 
GR (2012) Sustained translational repression by eIF2α-P medi-
ates prion neurodegeneration. Nature 485:507–511. doi:10.1038/
nature11058
 35. Schröder M, Kaufman RJ (2005) The mammalian unfolded pro-
tein response. Annu Rev Biochem 74:739–789. doi:10.1146/
annurev.biochem.73.011303.074134
 36. Sikorska B, Liberski PP, Giraud P, Kopp N, Brown P (2004) 
Autophagy is a part of ultrastructural synaptic pathology in 
Creutzfeldt–Jakob disease: a brain biopsy study. Int J Biochem 
Cell Biol 36:2563–2573. doi:10.1016/j.biocel.2004.04.014
 37. Suenaga T, Hirano A, Llena JF, Ksiezak-Reding H, Yen SH, 
Dickson DW (1990) Ubiquitin immunoreactivity in kuru 
plaques in Creutzfeldt–Jakob disease. Ann Neurol 28:174–177. 
doi:10.1002/ana.410280210
 38. Suraweera A, Münch C, Hanssum A, Bertolotti A (2012) Fail-
ure of amino acid homeostasis causes cell death following 
proteasome inhibition. Mol Cell 48:242–253. doi:10.1016/j.
molcel.2012.08.003
 39. Tanaka A, Cleland MM, Xu S, Narendra DP, Suen D-F, Kar-
bowski M, Youle RJ (2010) Proteasome and p97 mediate 
mitophagy and degradation of mitofusins induced by Parkin. J 
Cell Biol 191:1367–1380. doi:10.1083/jcb.201007013
 40. Titler AM, Posimo JM, Leak RK (2013) Astrocyte plasticity 
revealed by adaptations to severe proteotoxic stress. Cell Tissue 
Res 352:427–443. doi:10.1007/s00441-013-1571-4
 41. Vaden JH, Bhattacharyya BJ, Chen P-C, Watson JA, Marshall 
AG, Phillips SE, Wilson JA, King GD, Miller RJ, Wilson SM 
(2015) Ubiquitin-specific protease 14 regulates c-Jun N-terminal 
kinase signaling at the neuromuscular junction. Mol Neurode-
gener 10:3. doi:10.1186/1750-1326-10-3
 42. Wadsworth JDF, Powell C, Beck JA, Joiner S, Linehan JM, 
Brandner S, Mead S, Collinge J (2008) Molecular diagnosis of 
human prion disease. Methods Mol Biol Clifton NJ 459:197–
227. doi:10.1007/978-1-59745-234-2_14
425Acta Neuropathol (2016) 131:411–425 
1 3
 43. Wang K, Zhang J, Xu Y, Ren K, Xie W-L, Yan Y-E, Zhang 
B-Y, Shi Q, Liu Y, Dong X-P (2013) Abnormally upregu-
lated αB-crystallin was highly coincidental with the astro-
gliosis in the brains of scrapie-infected hamsters and human 
patients with prion diseases. J Mol Neurosci MN. doi:10.1007/
s12031-013-0057-x
 44. Xu Y, Tian C, Wang S-B, Xie W-L, Guo Y, Zhang J, Shi Q, 
Chen C, Dong X-P (2012) Activation of the macroautophagic 
system in scrapie-infected experimental animals and human 
genetic prion diseases. Autophagy 8:1604–1620. doi:10.4161/
auto.21482
 45. Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A (2001) 
Proteasomes and ubiquitin are involved in the turnover of the 
wild-type prion protein. EMBO J 20:5383–5391. doi:10.1093/
emboj/20.19.5383
 46. Zanotto-Filho A, Braganhol E, Battastini AMO, Moreira JCF 
(2012) Proteasome inhibitor MG132 induces selective apop-
tosis in glioblastoma cells through inhibition of PI3K/Akt and 
NFkappaB pathways, mitochondrial dysfunction, and activa-
tion of p38-JNK1/2 signaling. Invest New Drugs 30:2252–2262. 
doi:10.1007/s10637-012-9804-z
